Eli Lilly
About
Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical powerhouse that has become one of the most valuable companies in the world, driven by its dominance in diabetes care with Mounjaro and the blockbuster weight loss drug Zepbound (tirzepatide), alongside established franchises in oncology and immunology. Founded in 1876 and headquartered in Indianapolis, the company has experienced a dramatic surge in market capitalization as investors price in the massive addressable market for GLP-1 receptor agonist therapies for obesity and related metabolic conditions. As an investment, Eli Lilly offers exposure to what many analysts consider the most significant pharmaceutical opportunity in decades, with tirzepatide-based products potentially generating tens of billions in peak annual sales.
Mega Cap Stocks
Eli Lilly has surged into mega-cap territory driven by its revolutionary GLP-1 diabetes and obesity drugs Mounjaro and Zepbound, which represent one of the largest pharmaceutical opportunities in decades.
Pharmaceutical Stocks
Eli Lilly is a dominant pharmaceutical stock riding the unprecedented commercial success of its GLP-1 therapies Mounjaro and Zepbound, which have positioned the company at the forefront of the obesity treatment revolution and made it one of the most highly valued pharma companies in history.
Weight Loss Stocks
Eli Lilly has become one of the world's most valuable companies driven by its GLP-1 weight loss and diabetes drugs Mounjaro and Zepbound, leading the obesity treatment revolution.
Key Financials LLY
Price
$1,040.00
Change (1D)
+0.17%
Change (30D)
-3.23%
Change (60D)
+1.79%
Change (90D)
+23.07%
Change (180D)
+44.57%
Change (1Y)
+19.13%
Change (5Y)
+415.59%
P/E Ratio
54.74
EPS (TTM)
$19.00
52-Week Range
$623.78 — $1,133.95
50-Day MA
$1,049.85
Volume
2.70M
Data updated Feb 15 · Source: Twelve Data
